Opiate Treatment in Depression Refractory to Antidepressants and Electroconvulsive Therapy

Treatment resistant depression: methodological overview and operational criteria

Souery, D., Amsterdam, J. D., de Montigny, C., Lecrubier, Y., Montgomery, S., Lipp, O., Racagni, G., Zohar, J., & Mendlewicz, J. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)00004-2 · Cited by 443 · see citing works

Resistance to antidepressant medications and short-term clinical response to ECT

Prudic, J., Haskett, R. F., Mulsant, B. H., Malone, K. M., Pettinati, H. M., Stephens, S., Greenberg, R. M., Rifas, S., & Sackeïm, H. A. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.8.985 · Cited by 437 · see citing works

Buprenorphine Treatment of Refractory Depression

Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502000-00008 · Cited by 346 · see citing works

Regionally selective increases in μ opioid receptor density in the brains of suicide victims

Gross‐Isseroff, R., Dillon, K. A., Israeli, M., & Biegon, A. R. (1990) · Brain Research · doi:10.1016/0006-8993(90)91301-v · Cited by 221 · see citing works

Partial Response and Nonresponse to Antidepressant Therapy

Hirschfeld, R. M. A., Montgomery, S., Aguglia, E., Amore, M., Delgado, P. L., Gastpar, M., Hawley, C. J., Kasper, S. F., Linden, M., Massana, J., et al. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0913 · Cited by 193 · see citing works

β-Endorphin

Gerner, R. H. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780190040005 · Cited by 154 · see citing works

Possible antidepressive effects of opioids: Action of buprenorphine

Emrich, H. M., Vogt, P., & Herz, A. (1982) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1982.tb39483.x · Cited by 152 · see citing works

Depressive symptoms during buprenorphine treatment of opioid abusers

Kosten, T. R., Morgan, C., & Kosten, T. A. (1990) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(90)90035-o · Cited by 110 · see citing works

Clinical antidepressant activity of cyclazocine—a narcotic antagonist

Fink, M., SIMEON, J. G., Itil, T. M., & Freedman, A. M. (1970) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197011141 · Cited by 74 · see citing works

The opiate antagonist naloxone modifies the effects of electroconvulsive shock (ECS) on respiration, blood pressure and heart rate

Belenky, G. L., & Holaday, J. W. (1979) · Brain Research · doi:10.1016/0006-8993(79)90797-2 · Cited by 65 · see citing works

Current and Historical Concepts of Opiate Treatment in Psychiatric Disorders

Weber, M. M., & Emrich, H. M. (1988) · International Clinical Psychopharmacology · doi:10.1097/00004850-198807000-00007 · Cited by 57 · see citing works

Chemotherapy in Psychiatry

Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365 · see citing works

A brain-centric model of suicidal behavior

Mann, J. J., & Rizk, M. M. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081224 · Cited by 214 · see citing works

Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches

Peciña, M., Karp, J. F., Mathew, S. J., Todtenkopf, M. S., Ehrich, E. W., & Zubieta, J.-K. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0117-2 · Cited by 188 · see citing works

Opioid system and human emotions

Nummenmaa, L., & Tuominen, L. (2018) · British Journal of Pharmacology · doi:10.1111/bph.13812 · Cited by 178 · see citing works

Evaluation of Opioid Modulation in Major Depressive Disorder

Ehrich, E., Turncliff, R., Du, Y., Leigh-Pemberton, R., Fernandez, E., Jones, R., & Fava, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.330 · Cited by 169 · see citing works

The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review

Serafini, G., Adavastro, G., Canepa, G., De Berardis, D., Valchera, A., Pompili, M., Nasrallah, H., & Amore, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082410 · Cited by 162 · see citing works

Suicide Risk and Addiction: The Impact of Alcohol and Opioid Use Disorders

Rizk, M., Herzog, S., Dugad, S., & Stanley, B. (2021) · Current Addiction Reports · doi:10.1007/s40429-021-00361-z · Cited by 175 · see citing works

Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials

Carlezon, W. A., & Krystal, A. D. (2016) · Depression and Anxiety · doi:10.1002/da.22500 · Cited by 160 · see citing works

Sex Differences in Kappa Opioid Receptor Function and Their Potential Impact on Addiction

Chartoff, E. H., & Mavrikaki, M. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00466 · Cited by 134 · see citing works

Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors

Falcon, E., Browne, C. A., Leon, R. M., Fleites, V. C., Sweeney, R., Kirby, L. G., & Lucki, I. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.38 · Cited by 118 · see citing works

Bilateral Epidural Prefrontal Cortical Stimulation for Treatment-Resistant Depression

Nahas, Z. H., Anderson, B. S., Borckardt, J. J., Arana, A. B., George, M. S., Reeves, S. T., & Takacs, I. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.021 · Cited by 111 · see citing works

The opioid system in depression

Jelen, L. A., Stone, J. M., Young, A. H., & Mehta, M. A. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104800 · Cited by 102 · see citing works

Targeting opioid dysregulation in depression for the development of novel therapeutics

Browne, C. A., & Lucki, I. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.009 · Cited by 97 · see citing works

Effects of opioid- and non-opioid analgesics on responses to psychosocial stress in humans

Bershad, A. K., Miller, M. A., Norman, G. J., & de Wit, H. (2018) · Hormones and Behavior · doi:10.1016/j.yhbeh.2018.04.009 · Cited by 90 · see citing works

Lowered endogenous mu-opioid receptor availability in subclinical depression and anxiety

Nummenmaa, L., Karjalainen, T., Isojärvi, J., Kantonen, T., Tuisku, J., Kaasinen, V., Joutsa, J., Nuutila, P., Kalliokoski, K. K., Hirvonen, J., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0725-9 · Cited by 85 · see citing works

Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice

Falcón, E., Maier, K. L., Robinson, S. A., Hill‐Smith, T. E., & Lucki, I. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3723-y · Cited by 85 · see citing works

Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies

D, M. F. M., Thase, M. E., Trivedi, M. H., Ehrich, E. W., Martin, W. F., Memisoglu, A., Nangia, N., Stanford, A. D., Yu, M., & Pathak, S. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0284-1 · Cited by 83 · see citing works

Rapid-acting antidepressants

Witkin, J. M., Martin, A. E., Golani, L. K., Xu, N. Z., & Smith, J. L. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.03.002 · Cited by 75 · see citing works

Kappa Opioid Receptor Antagonists as Potential Therapeutics for Stress-Related Disorders

Jacobson, M. L., Browne, C. A., & Lucki, I. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023317 · Cited by 70 · see citing works

Augmentation Strategies in Electroconvulsive Therapy

Loo, C. K. A., Simpson, B., & MacPherson, R. (2010) · Journal of Ect · doi:10.1097/yct.0b013e3181e48143 · Cited by 69 · see citing works

The Prescription Opioid Addiction Treatment Study: What have we learned

Weiss, R. D., & Rao, V. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.12.001 · Cited by 68 · see citing works

Effects of buprenorphine on responses to social stimuli in healthy adults

Bershad, A. K., Seiden, J. A., & de Wit, H. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.09.011 · Cited by 64 · see citing works

NMDA antagonist treatment of depression

Williams, N., & Schatzberg, A. F. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.11.001 · Cited by 64 · see citing works

In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment of Major Depressive Disorder

Bidlack, J. M., Knapp, B. I., Deaver, D. R., Plotnikava, M., Arnelle, D. R., Wonsey, A. M., Toh, M. F., Pin, S. S., & Namchuk, M. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.249839 · Cited by 62 · see citing works

Antidepressant-like and anxiolytic-like effects following activation of the μ-δ opioid receptor heteromer in the nucleus accumbens

Kabli, N., Nguyen, T., Balboni, G., O’Dowd, B. F., & George, S. R. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.115 · Cited by 58 · see citing works

A role for the mu opioid receptor in the antidepressant effects of buprenorphine

Robinson, S. A., Erickson, R. L., Browne, C. A., & Lucki, I. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.10.050 · Cited by 58 · see citing works

Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine

Browne, C. A., Falcón, E., Robinson, S. A., Berton, O., & Lucki, I. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx079 · Cited by 56 · see citing works

Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?

Levinstein, M. R., Budinich, R. C., Bonaventura, J., Schatzberg, A. F., Zarate, C. A., & Michaelides, M. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240378 · Cited by 56 · see citing works

Antidepressant-like effects of buprenorphine in rats are strain dependent

Browne, C. A., Nest, D. S. V., & Lucki, I. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.10.014 · Cited by 45 · see citing works

Rapid-Acting Antidepressants

Witkin, J. M., Knutson, D. E., Rodriguez, G. J., & Shi, S. X.-Y. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180730104707 · Cited by 44 · see citing works

Novel Targets to Treat Depression: Opioid-Based Therapeutics

Browne, C. A., Jacobson, M. L., & Lucki, I. (2020) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000242 · Cited by 39 · see citing works

Impact of opioid agonist treatment on mental health in patients with opioid use disorder: a systematic review and network meta-analysis of randomized clinical trials

Zadeh, E. M., Ziafat, K., Yazdani, K., Kamel, M. M., Wong, J. S. H., Modabbernia, A., Blanken, P., Verthein, U., Schütz, C. G., Jang, K. L., et al. (2021) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2021.1887202 · Cited by 38 · see citing works

Use of Buprenorphine in treatment of refractory depression—A review of current literature

Stanciu, C. N., Glass, O., & Penders, T. M. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.01.015 · Cited by 37 · see citing works

Major Depressive Disorder and Kappa Opioid Receptor Antagonists.

Li, W., Sun, H., Chen, H., Yang, X., Li, X., Liu, R., Shao, L., & Qiu, Z. (2016) · PubMed · Cited by 36 · see citing works

Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework

Greenwald, M. K. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.08.003 · Cited by 32 · see citing works

Effects of Buprenorphine on Responses to Emotional Stimuli in Individuals with a Range of Mood Symptomatology

Bershad, A. K., Ruiz, N. A., & de Wit, H. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx077 · Cited by 32 · see citing works

Psychometric Evaluation of the Substance Use Risk Profile Scale (SURPS) in an Inpatient Sample of Substance Users Using Cue-Reactivity Methodology

Schlauch, R. C., Crane, C. A., Houston, R. J., Molnar, D. S., Schlienz, N. J., & Lang, A. R. (2014) · Journal of Psychopathology and Behavioral Assessment · doi:10.1007/s10862-014-9462-x · Cited by 32 · see citing works

Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3)

Zajecka, J., Stanford, A. D., Memisoglu, A., Martin, W. F., & Pathak, S. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s199245 · Cited by 31 · see citing works

Delta Opioid Receptors and Modulation of Mood and Emotion

Dripps, I. J., & Jutkiewicz, E. M. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_42 · Cited by 29 · see citing works

Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments

Machado‐Vieira, R., & Zarate, C. A. (2011) · Depression and Anxiety · doi:10.1002/da.20800 · Cited by 27 · see citing works

Management of depression in the presence of pain symptoms.

Mohr, P., Bitter, I., Svestka, J., Seifritz, E., Karamustafalioglu, O., Koponen, H., & Sartorius, N. (2010) · PubMed · Cited by 27 · see citing works

Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder

Namchuk, A. B., Lucki, I., & Browne, C. A. (2022) · Advances in Drug and Alcohol Research · doi:10.3389/adar.2022.10254 · Cited by 26 · see citing works

Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?

Peckham, A. M., Cruz, A. D. L., & Dufresne, R. L. (2018) · Mental Health Clinician · doi:10.9740/mhc.2018.07.175 · Cited by 25 · see citing works

Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System

COPLAN, P. M., Sessler, N. E., Harikrishnan, V., Singh, R., & Perkel, C. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2017.1269596 · Cited by 25 · see citing works

Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine

Adžić, M., Lukić, I., Mitić, M., Glavonic, E., Dragicevic-Curic, N., & Ivković, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121803 · Cited by 21 · see citing works

Opioid system modulators buprenorphine and samidorphan alter behavior and extracellular neurotransmitter concentrations in the Wistar Kyoto rat

Smith, K. L., Cunningham, J. I., Eyerman, D. J., Dean, R. L., Deaver, D. R., & Sánchez, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.11.015 · Cited by 21 · see citing works

The Black Book of Psychotropic Dosing and Monitoring

DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 22 · see citing works

The anxiolytic- and antidepressant-like effects of ATPM-ET, a novel κ agonist and μ partial agonist, in mice

Wang, Q., Long, Y., Hang, A., Zan, G., Shu, X. H., Wang, Y., & Liu, J. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4292-z · Cited by 20 · see citing works

Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder

Thase, M. E., Stanford, A. D., Memisoglu, A., Martin, W. F., Claxton, A., Bodkin, J. A., Trivedi, M. H., D, M. F. M., Yu, M., & Pathak, S. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0451-3 · Cited by 20 · see citing works

A meta-analysis of the potential antidepressant effects of buprenorphine versus placebo as an adjunctive pharmacotherapy for treatment-resistant depression

Dinoff, A., Lynch, S. T., Sekhri, N. K., & Klepacz, L. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.089 · Cited by 20 · see citing works

Mechanisms Underlying the Anti-Suicidal Treatment Potential of Buprenorphine

Cameron, C. M., Nieto, S. J., Bosler, L., Wong, M. H., Bishop, I., Mooney, L. J., & Cahill, C. M. (2021) · Advances in Drug and Alcohol Research · doi:10.3389/adar.2021.10009 · Cited by 20 · see citing works

Depression history as a predictor of outcomes during buprenorphine-naloxone treatment of prescription opioid use disorder

Peckham, A., Griffin, M. L., McHugh, R. K., & Weiss, R. D. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108122 · Cited by 19 · see citing works

Opioid system modulation of cognitive affective bias: implications for the treatment of mood disorders

Varastehmoradi, B., Wegener, G., Sánchez, C., & Smith, K. L. (2020) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000559 · Cited by 17 · see citing works

I like therefore I can, and I can therefore I like: the role of self-efficacy and affect in active inference of allostasis

Krupnik, V. (2024) · Frontiers in Neural Circuits · doi:10.3389/fncir.2024.1283372 · Cited by 19 · see citing works

Locomotor and anti-immobility effects of buprenorphine in combination with the opioid receptor modulator samidorphan in rats

Burke, N. N., Ferdousi, M. I., Deaver, D. R., Finn, D. P., Roche, M., & Kelly, J. P. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.12.012 · Cited by 13 · see citing works

Opioidergic Agents as Antidepressants: Rationale and Promise

Saxena, P. P., & Bodkin, J. A. (2018) · CNS Drugs · doi:10.1007/s40263-018-0584-7 · Cited by 13 · see citing works

Therapeutic Armamentarium for Treating Depression

Howland, R. H. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.07.2176 · Cited by 14 · see citing works

Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial

Pathak, S., Vince, B. D., Kelsh, D., Shram, M. J., Setnik, B., Lu, H. L., Nangia, N., Stanford, A. D., & Ehrich, E. W. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1280 · Cited by 12 · see citing works

Buprenorphine prevents stress-induced blunting of nucleus accumbens dopamine response and approach behavior to food reward in mice

Robinson, S. A., Hill‐Smith, T. E., & Lucki, I. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100182 · Cited by 11 · see citing works

Opioid Mechanisms and the Treatment of Depression

Jelen, L. A., Young, A. H., & Mehta, M. A. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_448 · Cited by 10 · see citing works

The Role of Dynorphin and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach

Clark, S. D. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_396 · Cited by 10 · see citing works

Antidepressants and the endogenous opioid system

Fricker, L. D., Osman, A., Gupta, A., Gomes, I., & Devi, L. A. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117392 · Cited by 9 · see citing works

Antipanic-like effect of esketamine and buprenorphine in rats exposed to acute hypoxia

Maraschin, J. C., Frias, A. T., Hernandes, P. M., Batistela, M. F., Martinez, L. M., Joca, S. R. L., Graeff, F. G., Audi, E. A., de Andrade, T. G. C. S., & Zangrossi, H. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113651 · Cited by 8 · see citing works

Therapeutic Potential of Buprenorphine in Depression: A Meta-Analysis of Current Evidence

Bhivandkar, S., Sarfraz, Z., Jain, L., Bachu, A. K., Malo, P. K., Hsu, M., Ayub, S., Poudel, L., Kumar, H., Loh, H., et al. (2024) · Journal of Clinical Medicine Research · doi:10.14740/jocmr5050 · Cited by 7 · see citing works

The use of buprenorphine in the treatment of drug-resistant depression – an overview of the studies

Stefanowski, B., Antosik-Wójcińska, A. Z., & Święcicki, Ł. (2020) · Psychiatria Polska · doi:10.12740/pp/102658 · Cited by 8 · see citing works

Comparative benefits of social housing and buprenorphine on wheel running depressed by morphine withdrawal in rats

Stickney, J. D., & Morgan, M. M. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05906-8 · Cited by 6 · see citing works

A Review of Therapeutics for Treatment-Resistant Depression in the Older Adult

Blaszczyk, A., Mathys, M., & Le, J. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01051-3 · Cited by 6 · see citing works

Rapid Improvement of Treatment-Resistant Major Depression During the Administration of Low-Dose Oxycodone

Magen, E., Geishin, A., & Lauden, A. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001311 · Cited by 5 · see citing works

Medication Treatments for Opioid Use Disorder: What Is the Impact on Mood and Mood Disorders?

Hassan, A. N., & Nunes, E. V. (2018) · Current Addiction Reports · doi:10.1007/s40429-018-0215-x · Cited by 5 · see citing works

Buprenorphine for the treatment of depression?

Balon, R. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12585 · Cited by 4 · see citing works

Endorphin Agonists for Severe Depression

Salerian, A. J. (2015) · Pharmacy & Pharmacology International Journal · doi:10.15406/ppij.2015.02.00017 · Cited by 3 · see citing works

Dual epidemics of deaths by heroin overdose and suicide

Salerian, A. J. (2017) · Clinical Research and Trials · doi:10.15761/crt.1000182 · Cited by 2 · see citing works

Major Depressive Disorder and Kappa Opioid Receptor

Li, W., Huijiao, S., Hao, C., Xicheng, Y., Li, X., Liu, R., Liming, S., & Zhui-bai, Q. (2016) · Translational Perioperative and Pain Medicine · doi:10.31480/2330-4871/035 · Cited by 2 · see citing works

The heroin epidemic (2000-2014): manmade influences

Salerian, A. J. (2018) · Pharmacy & Pharmacology International Journal · doi:10.15406/ppij.2018.06.00182 · Cited by 2 · see citing works

Opioid analgesics and narcotic antagonists

Ghodse, A. H., & Galea, S. (2011) · Side effects of drugs annual · doi:10.1016/b978-0-444-53741-6.00008-8 · Cited by 2 · see citing works

Association of PDYN 68-bp VNTR polymorphism with sublingual buprenorphine/naloxone treatment and with opioid or alcohol use disorder: Effect on craving, depression, anxiety and age onset of first use

Kaya-Akyüzlü, D., Özkan-Kotiloğlu, S., Şahiner, Ş. Y., ERTAN, E. A., & İlhan, İ. Ö. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174862 · Cited by 2 · see citing works

Opiates: Benefits and Overuse Potential

Salerian, A. J. (2015) · Pharmacy & Pharmacology International Journal · doi:10.15406/ppij.2015.02.00022 · Cited by 1 · see citing works

Opiates May Have Neuroprotective Properties against Neurodegeneration and Premature Death

Salerian, A. J. (2015) · Journal of Psychology & Clinical Psychiatry · doi:10.15406/jpcpy.2015.03.00144 · Cited by 1 · see citing works

Novel and Investigational Drugs in Depression

Shapiro, D. N., & Stahl, S. M. (2014) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2014/11590 · Cited by 1 · see citing works

Endorphin agonists for psychiatric disorders

Salerian, A. J. (2016) · Physical Medicine and Rehabilitation Research · doi:10.15761/pmrr.1000117 · Cited by 1 · see citing works

Antidepressant-Antianxiety Agents

Baldessarini, R. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3710-9_4 · Cited by 1 · see citing works

Depression Management during the Presence of Pain: An

Yılmaz, V., & Karadaş, Ö. (2015)

Treatment-resistant depression and the elephant in the room

Jenkins, E. (2010) · Summit (Simon Fraser University)

Impact of opioid agonists on mental health in substitution treatment for opioid use disorder: A systematic review and Bayesian network meta-analysis of randomized clinical trialsPreprint

Zadeh, E. M., Ziafat, K., Yazdani, K., Mamdouh, M., Wong, J. S. H., Modabbernia, A., Blanken, P., Verthein, U., Schütz, C. G., Jang, K. L., et al. (2020) · medRxiv · doi:10.1101/2020.07.04.20146506

Antidepressants

(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372997.as03

Antidepressants

(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372300.as03

Chapter 3. Antidepressants

(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551289.cd03

Opioid agents for treatment-resistant depression

Serafini, G., Adavastro, G., Canepa, G., Amerio, A., Aguglia, A., & Amore, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00016-5

The Interaction Between Mental Distress and Opioid Maintenance Treatment Impacts Levels of Circulating Cytokines

Nygaard-Odeh, K., Soloey-Nilsen, H., Kristiansen, M. G., Brekke, O., Mollnes, T. E., Berk, M., & Bramness, J. G. (2026) · Addiction Biology · doi:10.1111/adb.70147

Brixadi for Stimulant Use Disorder: Evolving Pharmacologic Considerations and Clinical Implications

Sawaya, M. F., McNulty, M. E., Germain, C. J. S., Hachem, I. A., Calix, M. S., Lormand, R. M., McComb, N., Shehab, A. A. A., Wrightson, J., Anwar, A. I., et al. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03772-4

P.2.065 Opiate treatment in ECT-resistant depression

(2005) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(05)80854-5

Treatment Augmentation With Opiates in Severe and Refractory Major Depression

Stoll, A. L., & Rueter, S. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.12.2017 · Cited by 102 · see citing works

Treatment-Refractory OCD Responding to Maintenance Electroconvulsive Therapy

Raveendranathan, D., Srinivasaraju, R., Ratheesh, A., Math, S. B., & Reddy, Y. C. J. (2012) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.11060124 · Cited by 15 · see citing works

Options for treatment-resistant depression. Why electroconvulsive therapy may be the best alternative to medication.

(2009) · PubMed

Ketamine and Electroconvulsive Therapy for Treatment-Refractory Depression

Huang, X., & Zheng, W. (2023) · ALPHA PSYCHIATRY · doi:10.5152/alphapsychiatry.2023.231358 · Cited by 38 · see citing works